Industry veteran Kristen Sosa joins Caleres as Division President, taking the helm of a portfolio including Stuart Weitzman, Veronica Beard, and Favorite Daughter, signaling a strategic push for growth.
Soybean futures traded lower midday Monday, pressured by mixed export figures and a growing Brazilian harvest. The market also digested news of a potential U.S.-India trade deal that could impact agricultural flows.
Oracle's ambitious plan to raise up to $50 billion for AI infrastructure has triggered volatile swings in its share price, reflecting broader investor anxiety over the massive capital demands of the artificial intelligence arms race.
After a tumultuous period of bankruptcy and closures, TGI Fridays CEO Ray Blanchette is steering a deeply personal turnaround. Early results from holiday pop-ups and a revamped brand voice show promise, but the road to 1,000 restaurants remains steep.
TD Cowen and H.C. Wainwright have raised price targets on KalVista Pharmaceuticals, expressing confidence in its oral hereditary angioedema treatment ahead of the company's fourth-quarter financial results.
Clinical-stage biotech Erasca (ERAS) has seen its stock skyrocket over the past 12 months, hitting a multi-year high. While technical momentum is strong, the company remains pre-revenue, with its fate tied to future drug approvals, presenting a classic high-risk, high-reward scenario for investors.
As artificial intelligence reshapes finance, we examine whether XRP's underlying technology is built to capitalize on the trend of 'agentic AI' handling transactions, or if its potential benefits remain speculative.
A significant reset in analyst price targets for iRhythm Holdings (IRTC) is prompting investors to reassess the cardiac monitoring firm's risk-reward profile. This shift reflects evolving views on reimbursement headwinds, competitive pressures, and long-term growth catalysts in the digital health sector.
Novo Nordisk launches its first oral GLP-1 weight-loss drug with strong early demand, reports positive Phase 3 results for CagriSema, and expands a cell therapy partnership for diabetes. These moves come as investors reevaluate the company's long-term growth prospects amid competitive and pricing pressures.
London's blue-chip index surged to a historic high as investors rotated into defensive sectors, shrugging off a brutal sell-off in precious metals and oil triggered by geopolitical shifts and regulatory moves.
A historic winter storm has plunged American Airlines into its worst weather-related crisis, stranding crews and passengers while wiping up to $200 million from its revenue, exposing deep-seated recovery challenges.
As global leaders gather in Davos, a coalition of over 400 affluent individuals from 24 nations issues a stark demand: governments must impose higher taxes on the ultra-wealthy to tackle inequality.
A new Deloitte report urges enterprises to embed accountability and oversight from the start, arguing that governance is not a barrier but an accelerator for scaling autonomous AI systems.
Former Congressman Colin Allred delivers a pointed public rebuke of Texas House member James Talarico, alleging derogatory comments were made during the heated Democratic Senate primary campaign.
CNBC's Jim Cramer lauds Salesforce's operational strength, yet the stock, alongside peer ServiceNow, faces persistent 'multiple compression' as Wall Street reevaluates growth expectations for mature software leaders.
CNBC's Jim Cramer reaffirmed his bullish stance on Palantir Technologies during a recent 'Mad Money' segment, placing the data analytics firm in the same league as established giants like ServiceNow and Salesforce.
CNBC's Jim Cramer highlights a dramatic turnaround for Meta Platforms, arguing its heavy investment in artificial intelligence is fundamentally reshaping the company's trajectory and market perception.
The Priestly Society of St. Pius X (SSPX) announced plans to consecrate new bishops in July without Vatican approval, escalating a decades-long doctrinal standoff and prompting concerns of a permanent rupture within the Catholic Church.
A 65-year-old Thai tourist was killed by a bull elephant with a known history of aggression in Khao Yai National Park, marking the animal's third human fatality and prompting urgent discussions on wildlife management strategies.
BioNTech's stock faces pressure following a Leerink Partners downgrade, which tempered near-term optimism around its oncology pipeline after a recent rally. The move highlights investor reassessment of catalysts amid mixed long-term performance.
